Sanofi Acquires Kadmon, its Novel GVHD Therapy and China JV
September 08, 2021 at 05:57 AM EDT
France 's Sanofi will acquire Kadmon Holdings of New York City in a $1.9 billion deal. In 2019, Kadmon formed a JV with BioNova Pharma to develop its novel lead drug, Rezurock (belumosudil) in China . One month ago, Kadmon was approved to launch Rezurock in the US as a third-line treatment for graft-versus-host disease. Sanofi said it would begin commercializing the drug as part of its GVHD portfolio. Kadmon was also supported by at least one China-connected VC, Vivo Ventures. More details.... Stock Symbol: (NSDQ: KDMN) Share this with colleagues: // //
